| Field | Specification |
|---|---|
| Organism | |
| Applications | |
| Tissue | |
| Disease | Laryngeal squamous cell carcinoma |
| Growth properties | |
| Biosafety level | |
| Product format | Frozen |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Overview
Developed from a laryngeal squamous cell carcinoma of a cat. The cells were stably transfected with a plasmid containing a luciferase-YFP fusion construct.
Key elements and design rationale
- Model identity: SCCF1 Stably Expressing Luciferase Cell Line is supplied as a tumor cell line derived from Cat larynx.
- Growth properties: Adherent, epithelial-like
- Growth conditions: PriCoat™ T25 Flasks (G299) or Applied Cell Extracellular Matrix (G422) are recommended for optimal cell culture. PriGrow III (TM003) + 10% FBS(Regular*) + 1% Penicillin/Streptomycin Solution (G255), 37.0°C, 5% CO₂. 0.4 mg/ml Geneticin/G418 (G271) for selection. Note: Selection drugs should be added to the culture medium after the first passage to ensure cells have recovered from freeze-thaw conditions. *Do not heat-inactivate
- Engineering / immortalization: Luciferase reporter expression.
- Product format: Frozen, BSL-2
This cell-based model is generally used in larynx biology, phenotype comparison, and assay development studies. Donor/background information is available for contextual interpretation.
Biological background
SCCF1 cells can be used for experiments on genetic dysregulation in neoplastic keratinocytes of the feline oropharynx. Will form tumors in nude mice, but do not readily invade bone. These cells are a useful in vitro model for head and neck cancer. Donor/background information provided for this product: Cat, Laryngeal squamous cell carcinoma.
Research relevance and current trends
- Cell-line models continue to be used for tumor phenotype comparison, pathway perturbation studies, and assay development in controlled in vitro systems.
- Engineered and subtype-defined tumor lines are often used to compare growth behavior, reporter output, and response patterns across matched experimental conditions.
- When metastatic or lineage features are described, investigators commonly interpret results alongside morphology, passage history, and culture environment.
Common research applications
- Cancer biology studies that compare proliferation-associated behavior, morphology, and pathway responses in vitro.
- Assay development for treatment response, reporter monitoring, or phenotype comparison under matched culture conditions.
- Side-by-side comparison of engineered versus parental background characteristics when relevant to the study design.
Changes in morphology, growth rate, viability, or reporter signal are typically interpreted together with passage history, culture matrix, and the specified growth conditions for the model.
Notes for experimental interpretation
- Morphology, doubling behavior, and reporter or marker output can shift with passage number, substrate choice, and medium composition; these variables should be recorded alongside experimental readouts.
- Matched controls such as parental cells, untreated cultures, or parallel cultures maintained under identical conditions help distinguish background effects from biology of interest.
Culture and product details
- Growth Conditions: PriCoat™ T25 Flasks (G299) or Applied Cell Extracellular Matrix (G422) are recommended for optimal cell culture. PriGrow III (TM003) + 10% FBS(Regular*) + 1% Penicillin/Streptomycin Solution (G255), 37.0°C, 5% CO₂. 0.4 mg/ml Geneticin/G418 (G271) for selection. Note: Selection drugs should be added to the culture medium after the first passage to ensure cells have recovered from freeze-thaw conditions. *Do not heat-inactivate
- Split Ratio: 1:5
—
🧊 Thawing Protocol
- Thaw cells quickly in a 37°C water bath while agitating gently (maximum 2 minutes). The vial cap should be kept above the water level to minimize the risk of contamination.
- Decontaminate the vial by spraying and wiping the exterior of the vial with 70% ethanol. From this point onwards, all operations should be strictly carried out inside a biological safety cabinet using aseptic conditions.
- Transfer the cell suspension into a 15ml sterile conical tube containing 5ml of pre-warmed, complete growth media. Centrifuge cells at 125xg for 5-7 minutes.
- Aspirate the supernatant without disturbing the cell pellet. Re-suspend the cell pellet in the recommended pre-warmed, complete growth media and dispense into a T25 culture flask.
- Incubate the cells at the recommended conditions.
🔬 Subculture Protocol
Volumes given below are for a T75 flask; proportionally increase or decrease the volume as required per culture vessel size. Subculture cells once the culture vessel is 80% confluent.
- Aspirate the culture media, and add 2-3ml of pre-warmed 0.25% Trypsin-EDTA to the culture vessel.
- Observe the cells under a microscope to confirm detachment (typically within 2-10 minutes). Cells that are difficult to detach can be put in 37°C, for several minutes to facilitate detachment.
- Neutralize Trypsin-EDTA by adding an equal volume of the complete growth media into the culture vessel.
- Transfer the culture suspension into a sterile centrifuge tube, and centrifuge at 125xg for 5 minutes. The actual centrifuge duration and speed may vary depending on the cell type.
- Aspirate the supernatant, and re-suspend the pellet with pre-warmed fresh complete growth media. Add appropriate aliquots of the cell suspension to new culture vessels, as desired.
- Incubate the cells at the recommended conditions.
How should I handle live cells once I receive them?
Please refer to our Cell Handling and Thawing Guidelines for detailed instructions on receiving, thawing, and culturing live cells:
https://www.abmgood.com/immortalized-cells-documents.html
Following these guidelines will help ensure optimal cell viability and performance.
https://www.abmgood.com/immortalized-cells-documents.html
Following these guidelines will help ensure optimal cell viability and performance.
Why are these cells classified as biosafety level II?
We follow the CDC-NIH recommendations that all mammalian sourced products should be handled at the Biological Safety Level 2 to minimize exposure of potentially infectious products. This information can be found in 'Biosafety in Microbiological and Biomedical Laboratories' (1999). Your institution's Safety Officer or Technical Services will be able to make the call as to whether BioSafety Level I is possible with these cells at your site, if desired.
What is your warranty or return policy?
Our warranty and return policy is outlined in abm’s Terms and Conditions, including details on product quality, limitations, and claims.
Please refer to the following link for full information:
https://www.abmgood.com/terms
For additional questions, our Order team is happy to assist and can be reached at order@abmgood.com.
Please refer to the following link for full information:
https://www.abmgood.com/terms
For additional questions, our Order team is happy to assist and can be reached at order@abmgood.com.
How many times can cells divide?
The number of times cells can divide depends on the cell type:
Primary cells have a limited lifespan and will undergo a finite number of population doublings before entering senescence. The exact number varies by cell type and culture conditions.
Immortalized cell lines are capable of extended or indefinite proliferation under proper culture conditions, although growth characteristics may vary between lines.
Primary cells have a limited lifespan and will undergo a finite number of population doublings before entering senescence. The exact number varies by cell type and culture conditions.
Immortalized cell lines are capable of extended or indefinite proliferation under proper culture conditions, although growth characteristics may vary between lines.
Do I need Applied Cell Extracellular Matrix (G422) if I am using PriCoat™ flasks?
Please refer to the Growth Conditions section of your specific product page. This section will indicate whether Applied Cell Extracellular Matrix (G422), PriCoat™ flasks, or both are recommended for optimal cell attachment and growth, as requirements may vary by cell type.
Cell line sourcing and selection (species, tissue, and disease model matching) · Stable cell line engineering (overexpression, knockdown, knockout via CRISPR/Cas9, shRNA, sgRNA) · Reporter gene integration (GFP, RFP, luciferase, fluorescent/bioluminescent constructs) · Genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles) · Inducible expression systems (Tet-On/Off and regulatable constructs) · Drug resistance marker selection (puromycin, G418, hygromycin, and others) · Custom growth and media optimisation for specific assay requirements · Scale-up production for high-throughput screening campaigns · Authentication and QC services (STR profiling, mycoplasma testing, viability assessment). Talk to a Scientist or contact support@biohippo.com.
Tannehill-Gregg, S., Kergosien, E., & Rosol, T. J. (2001). Feline head and neck squamous cell carcinoma cell line: characterization, production of parathyroid hormone-related protein, and regulation by transforming growth factor-beta. In vitro cellular & developmental biology. Animal, 37(10), 676–683. https://doi.org/10.1290/1071-2690(2001)037
Tannehill-Gregg, S. H., Levine, A. L., & Rosol, T. J. (2006). Feline head and neck squamous cell carcinoma: a natural model for the human disease and development of a mouse model. Veterinary and comparative oncology, 4(2), 84–97. https://doi.org/10.1111/j.1476-5810.2006.00096.x
Heller, D. A., Fan, T. M., de Lorimier, L. P., Charney, S. C., Barger, A. M., Tannehill-Gregg, S. H., Rosol, T. J., & Wallig, M. A. (2007). In vitro cyclooxygenase-2 protein expression and enzymatic activity in neoplastic cells. Journal of veterinary internal medicine, 21(5), 1048–1055. https://doi.org/10.1892/0891-6640(2007)21[1048:ivcpea]2.0.co;2
Wypij, J. M., Fan, T. M., Fredrickson, R. L., Barger, A. M., de Lorimier, L. P., & Charney, S. C. (2008). In vivo and in vitro efficacy of zoledronate for treating oral squamous cell carcinoma in cats. Journal of veterinary internal medicine, 22(1), 158–163. https://doi.org/10.1111/j.1939-1676.2007.0010.x
Bergkvist, G. T., Argyle, D. J., Morrison, L., MacIntyre, N., Hayes, A., & Yool, D. A. (2011). Expression of epidermal growth factor receptor (EGFR) and Ki67 in feline oral squamous cell carcinomas (FOSCC). Veterinary and comparative oncology, 9(2), 106–117. https://doi.org/10.1111/j.1476-5829.2010.00239.x
Bergkvist, G. T., Argyle, D. J., Pang, L. Y., Muirhead, R., & Yool, D. A. (2011). Studies on the inhibition of feline EGFR in squamous cell carcinoma: enhancement of radiosensitivity and rescue of resistance to small molecule inhibitors. Cancer biology & therapy, 11(11), 927–937. https://doi.org/10.4161/cbt.11.11.15525
Wakshlag, J. J., Peters-Kennedy, J., Bushey, J. J., & Loftus, J. P. (2011). 5-lipoxygenase expression and tepoxalin-induced cell death in squamous cell carcinomas in cats. American journal of veterinary research, 72(10), 1369–1377. https://doi.org/10.2460/ajvr.72.10.1369
E. Balkman, C. , L. Gieger, T. , M. Zgola, M. , D. Lewis, L. and C. McEntee, M. (2012) In Vitro Characterization of Docetaxel as a Radiosensitizer in Canine and Feline Cancer Cell Lines. Open Journal of Veterinary Medicine, 2, 285-292. doi: 10.4236/ojvm.2012.24045.
Martin, C. K., Dirksen, W. P., Shu, S. T., Werbeck, J. L., Thudi, N. K., Yamaguchi, M., Wolfe, T. D., Heller, K. N., & Rosol, T. J. (2012). Characterization of bone resorption in novel in vitro and in vivo models of oral squamous cell carcinoma. Oral oncology, 48(6), 491–499. https://doi.org/10.1016/j.oraloncology.2011.12.012
Pang, L. Y., Bergkvist, G. T., Cervantes-Arias, A., Yool, D. A., Muirhead, R., & Argyle, D. J. (2012). Identification of tumour initiating cells in feline head and neck squamous cell carcinoma and evidence for gefitinib induced epithelial to mesenchymal transition. Veterinary journal (London, England : 1997), 193(1), 46–52. https://doi.org/10.1016/j.tvjl.2012.01.009
Jackie M. Wypij et al., Surrogate biomarkers interleukin-6 and interleukin-10 in a spontaneous feline model of head and neck squamous cell carcinoma (HNSCC).. JCO 32, e17056-e17056(2014).doi:10.1200/jco.2014.32.15_suppl.e17056
Brown, M. E., Bear, M. D., Rosol, T. J., Premanandan, C., Kisseberth, W. C., & London, C. A. (2015). Characterization of STAT3 expression, signaling and inhibition in feline oral squamous cell carcinoma. BMC veterinary research, 11, 206. https://doi.org/10.1186/s12917-015-0505-7
Parviainen, S., Autio, K., Vähä-Koskela, M., Guse, K., Pesonen, S., Rosol, T. J., Zhao, F., & Hemminki, A. (2015). Incomplete but infectious vaccinia virions are produced in the absence of oncolysis in feline SCCF1 cells. PloS one, 10(3), e0120496. https://doi.org/10.1371/journal.pone.0120496
Supsavhad, W., Dirksen, W. P., Hildreth, B. E., & Rosol, T. J. (2016). p16, pRb, and p53 in Feline Oral Squamous Cell Carcinoma. Veterinary sciences, 3(3), 18. https://doi.org/10.3390/vetsci3030018
Supsavhad, W., Dirksen, W. P., Martin, C. K., & Rosol, T. J. (2016). Animal models of head and neck squamous cell carcinoma. Veterinary journal (London, England : 1997), 210, 7–16. https://doi.org/10.1016/j.tvjl.2015.11.006
10%
OFF
20%
OFF
$50
OFF
FREE
SAMPLE
